These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 12490774)

  • 1. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol.
    Inada T; Beasley CM; Tanaka Y; Walker DJ
    Int Clin Psychopharmacol; 2003 Jan; 18(1):39-48. PubMed ID: 12490774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol.
    Inada T; Yagi G; Miura S
    Schizophr Res; 2002 Oct; 57(2-3):227-38. PubMed ID: 12223254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
    Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM
    J Clin Psychiatry; 1997 May; 58(5):205-11. PubMed ID: 9184614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
    Carlson CD; Cavazzoni PA; Berg PH; Wei H; Beasley CM; Kane JM
    J Clin Psychiatry; 2003 Aug; 64(8):898-906. PubMed ID: 12927004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.
    Allan ER; Sison CE; Alpert M; Connolly B; Crichton J
    Psychopharmacol Bull; 1998; 34(1):71-4. PubMed ID: 9564201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America.
    Costa e Silva JA; Alvarez N; Mazzotti G; Gattaz WF; Ospina J; Larach V; Starkstein S; Oliva D; Cousins L; Tohen M; Taylor CC; Wang J; Tran PV
    J Clin Psychopharmacol; 2001 Aug; 21(4):375-81. PubMed ID: 11476121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosing the antipsychotic medication olanzapine.
    Nemeroff CB
    J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials.
    Cavazzoni PA; Berg PH; Kryzhanovskaya LA; Briggs SD; Roddy TE; Tohen M; Kane JM
    J Clin Psychiatry; 2006 Jan; 67(1):107-13. PubMed ID: 16426096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
    Lieberman JA; Tollefson G; Tohen M; Green AI; Gur RE; Kahn R; McEvoy J; Perkins D; Sharma T; Zipursky R; Wei H; Hamer RM;
    Am J Psychiatry; 2003 Aug; 160(8):1396-404. PubMed ID: 12900300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.
    Wright P; Lindborg SR; Birkett M; Meehan K; Jones B; Alaka K; Ferchland-Howe I; Pickard A; Taylor CC; Roth J; Battaglia J; Bitter I; Chouinard G; Morris PL; Breier A
    Can J Psychiatry; 2003 Dec; 48(11):716-21. PubMed ID: 14733451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine versus haloperidol treatment in first-episode psychosis.
    Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
    Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.
    Schillevoort I; de Boer A; Herings RM; Roos RA; Jansen PA; Leufkens HG
    Ann Pharmacother; 2001 Dec; 35(12):1517-22. PubMed ID: 11793611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.
    Ishigooka J; Inada T; Miura S
    Psychiatry Clin Neurosci; 2001 Aug; 55(4):403-14. PubMed ID: 11442893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
    Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
    Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.
    Wright P; Meehan K; Birkett M; Lindborg SR; Taylor CC; Morris P; Breier A
    Clin Ther; 2003 May; 25(5):1420-8. PubMed ID: 12867218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
    Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH
    Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia.
    Suzuki H; Gen K; Takahashi Y
    Hum Psychopharmacol; 2014 Jan; 29(1):83-8. PubMed ID: 24424709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
    Kennedy JS; Jeste D; Kaiser CJ; Golshan S; Maguire GA; Tollefson G; Sanger T; Bymaster FP; Kinon BJ; Dossenbach M; Gilmore JA; Breier A
    Int J Geriatr Psychiatry; 2003 Nov; 18(11):1013-20. PubMed ID: 14618553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
    Conley RR; Tamminga CA; Bartko JJ; Richardson C; Peszke M; Lingle J; Hegerty J; Love R; Gounaris C; Zaremba S
    Am J Psychiatry; 1998 Jul; 155(7):914-20. PubMed ID: 9659857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.